News

VaLogic Bio Acquires Facility Logix to Expand Life Sciences Facility Services

VaLogic Bio, a platform company of 424 Capital and a leading provider of compliance and SaaS services to the life sciences industry, proudly announces the acquisition of Facility Logix (FLGX), a renowned firm specializing in planning, developing, and project management for life sciences facilities. This acquisition aligns with VaLogic Bio’s strategic vision to enhance its capabilities and broaden its footprint in the life sciences sector.

With this acquisition, VaLogic Bio will leverage Facility Logix’s current service offerings to build a market-leading, full-service outsourced solutions platform. This platform aims to enable life science and biotechnology companies to remain GMP compliant through advisory, project management, procurement, technical equipment servicing, facility design/engineering and construction, environmental monitoring, and CQV services. These services will help clients run their labs and manufacturing suites more efficiently, allowing them to focus on advancing life-saving therapeutics. The combined company provides clients an unparalleled suite of services, from initial facility concept to operational readiness and ongoing compliance.

As part of the acquisition, Pat Larrabee, formerly the CEO and founder of Facility Logix, will become the Vice President of Advisory Services and join the VaLogic Bio leadership team.

The former Facility Logix team will continue to operate out of its Montgomery County, Maryland office in Burtonsville. With its proven track record, the team will continue to deliver high-quality, conflict-free services, ensuring a seamless and uninterrupted transition for existing clients and partners.

“The successful relationship between our firms has developed over many years of working together to support mutual clients in the Maryland market,” noted VaLogic Bio CEO Bill Robertson. “We are enthusiastic about permanently joining forces and further expanding our services and client base. Pat is well respected as a trusted advisor and leader and has deep national market knowledge.”

“We are excited about joining forces with VaLogic Bio,” commented Larrabee.

With the acquisition of Facility Logix, VaLogic Bio’s team now totals 72 employees, with offices in Texas and two offices in Maryland. This acquisition represents a significant step forward in VaLogic Bio’s unwavering commitment to simplifying compliance and ensuring peace of mind for life sciences organizations. By combining the strengths of both companies, VaLogic Bio is well-positioned to lead the industry in delivering innovative, efficient, and compliant solutions for life sciences facilities.

“I am very proud of our team’s capabilities and our portfolio of work over the past two decades,” said Larrabee. “And with the added capabilities of VaLogic Bio and the financial support of 424 Capital, we are poised to capture additional market share.”

For more information about the acquisition or to learn more about the services offered by VaLogic Bio, please visit www.valogicbio.com

Recent News

07/23/2026

Activation Capital Expands the Bio+Tech Center, Doubling Laboratory Capacity to Strengthen Virginia’s Life Sciences Entrepreneurship and Innovation Ecosystem

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced an expansion of its Bio+Tech Center to support the continued growth of life sciences entrepreneurship across the region. Activation Capital’s Bio+Tech Center is a life sciences incubator located within the Virginia Bio+Technology Research Park. Serving as both a physical and programmatic

07/22/2026

Epidarex Announces Leadership Appointments

With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen our impact across the US and UK life science ecosystems, recognizing and elevating exceptional talent within our team is a vital part of that journey. These transitions reflect our continued

07/22/2026

Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer

Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO), dedicated to strengthening the nation’s pharmaceutical supply chain and protecting America’s medicine cabinet, today announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer. Venkatraman brings more than 25 years of experience in pharmaceutical development, process chemistry, manufacturing, and scientific leadership. He